Can a cholesterol drug help immunotherapy work again in lung cancer?

NCT ID NCT05553834

Ongoing Disease control Sponsor: Duke University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether adding a cholesterol-lowering drug (alirocumab) to an immunotherapy drug (cemiplimab) can shrink tumors in people with advanced lung cancer whose disease got worse after standard immunotherapy. About 60 participants will receive both drugs every few weeks. The main goal is to see how many patients respond to the combination.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Alirocumab and cemiplimab combination
What this could lead to: If successful, this could offer a new treatment option for people with lung cancer that stopped responding to standard immunotherapy.
What could go wrong: This is a small, early-phase trial (60 people) with no control group. The combination may not work better than existing treatments and could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER (NSCLC)

Contacts and locations

Locations

Duke University

Durham, North Carolina, 27705, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.